The EU-GMP wall no Thai cannabis export model has cleared

Ask any investor pitching Thailand's cannabis upside and the export story arrives on schedule: cheap, abundant biomass, a tropical growing season, and a straight line to European shelves. That line does not exist yet. It cannot exist until a certificate is issued that, as of today, has never been issued to a single Thai producer.

This matters because the export leg is not a footnote in the bull case. It is load-bearing. Every optimistic total-market forecast for Thailand, including the incumbent figures near $7.1 billion, $9.18 billion, and $9.6 billion by 2030, assumes Thai product eventually reaches high-value regulated markets abroad at scale. Strip the export leg out and those models lose the growth engine that gets them from a contracting domestic market to a number nearly six times the 2024 peak. So it is worth asking a narrow, answerable question: can Thai cannabis legally enter the European Union today as a finished product under a Thai manufacturing credential. The answer is no, and it is not close.

What a live registry query actually shows

The European Union's own database of manufacturing authorizations, EudraGMDP, is the authoritative record of who holds EU-GMP certification for finished pharmaceutical and medicinal-cannabis products. A live query of that register on 02 July 2026 returns zero cannabis finished-product EU-GMP certifications of any kind for Thailand Certain. Not zero at one company. Zero at the country level. No Thai facility appears in the register as a holder of a finished-product cannabis manufacturing authorization recognized under EU-GMP.

That is a precise claim and it is worth stating precisely, because the imprecise version of it gets repeated constantly and is false. It is not true that Thailand has no GMP certifications of any kind. Thailand has domestic GMP infrastructure, and Thai facilities hold various certifications for various purposes. What does not exist is a Thai-held EU-GMP certification for a finished cannabis product, the specific credential that lets that product be sold as a manufactured medicinal good inside the European Union. That is the wall. It is narrow, and it is exactly the wall that matters for the export thesis.

"Alignment" is a marketing word, not a regulatory status

The gap between the two claims, no GMP at all versus no EU-GMP finished-product certificate, is where a lot of investor confusion gets manufactured. Search for Thai cannabis producers and European market access and you will find companies describing their facilities as EU-GMP aligned, EU-GMP compliant in practice, or built to EU-GMP standards. Read those phrases as marketing language, not regulatory status. Alignment is not a held certificate. A facility can be built to the right specifications, run the right documentation, and still not hold the authorization that a national competent authority in the EU issues after its own inspection and approval process. Until that inspection happens and that authorization is granted, "aligned" describes an intention, not a credential a customs official or a pharmacy wholesaler can act on.

This is not a paperwork technicality that resolves itself quietly in the background. EU-GMP certification for a finished cannabis product is a multi-year process involving facility inspection by an EU member state authority, validated manufacturing processes, and ongoing compliance obligations. No Thai operator has completed it. None is close enough to have appeared in the register as of the July query.

How Thai material reaches Europe today: GMP washing

None of this means Thai-origin cannabis is entirely absent from European supply chains. It means the route it takes is not the one investor decks usually draw. Thai flower and extract that does reach Europe today typically arrives as a raw or intermediate input, then gets finished, processed, or repackaged under someone else's EU-GMP certification in a third country, most often within Europe itself or in a jurisdiction that already holds the credential. The industry has a name for this: GMP washing. The Thai-grown material supplies the biomass. A licensed facility elsewhere supplies the compliance status. The value that accrues to the certified finisher, not to the Thai grower, is exactly the value an export-led Thailand forecast needs flowing the other way.

This arrangement is not a scandal or a secret; it is a rational response to a real regulatory gap, and it works fine as a stopgap. What it is not is a scalable national export channel. GMP washing caps how much value Thailand captures per kilogram shipped, because the highest-margin step in the chain, finished-product manufacturing under a held certificate, happens somewhere else. A market thesis that models Thailand capturing full finished-product export economics is modeling a step that has not happened yet.

What this does, and does not, mean for the domestic thesis

None of this is a recriminalization signal or a reason to expect the license framework to tighten. The regulatory direction in Thailand is entrenchment of the medical model established since flower became a controlled herb under traditional-medicine law on 25 June 2025, requiring a PT 33 prescription, with cannabis still off the narcotics list while extracts above 0.2% THC remain Category 5 narcotics. The live domestic risk is oversupply and price compression inside a shrinking, consolidating retail base, not a ban and not, in the near term, a resolved export channel.

What it means concretely for export-dependent volume and value: the tonnage that Thailand could plausibly move into EU-GMP-gated channels today, and the value that tonnage would carry if it moved through GMP-washing arrangements instead of direct Thai-certified export, are both figures worth having exact numbers for before committing capital to an export-led thesis. Both are reconstructed and confidence-tagged in the full report. Export tonnage sits at Likely, and the value Thailand actually captures under current routing sits at Likely. see both in the report →

The gap between those two figures is the GMP-washing tax, and it is the single most consequential number missing from every public export narrative on Thailand.

How we know this

The EU-GMP finding is a registry fact, not a field estimate: EudraGMDP is a public database, and the query behind this post was run live on 02 July 2026 against the current record. The routing mechanics around it, how Thai material actually moves once it leaves the country and where it gets finished, were mapped against the same ground-level program behind the rest of our work: 850+ dispensaries visited across Thailand, including 650 in Bangkok, 100+ owner and operator interviews spanning ten-plus nationalities, 30+ farm operators, and the licensing process completed first-hand rather than reconstructed from filings. Export routing is a supply-chain question, and supply-chain questions get answered by talking to the people moving the product, not by reading a press release about "EU-GMP alignment."